[{"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-001", "question": "A 52-year-old man with primary sclerosing cholangitis and ulcerative colitis maintained on vedolizumab presents with progressive jaundice, pruritus, and weight loss over 3 months. MRCP shows a dominant stricture at the hepatic hilum with intrahepatic ductal dilation. CA 19-9 is 180 U/mL. Brush cytology from ERCP is suspicious but not diagnostic for malignancy. PET-CT shows FDG avidity at the stricture with standardized uptake value (SUV) max of 6.2. Which of the following is the most appropriate next step in management?", "options": ["Proceed directly to liver transplantation without biopsy confirmation given high suspicion for cholangiocarcinoma in PSC", "Perform endoscopic ultrasound with fine-needle aspiration of the hilar mass", "Initiate neoadjuvant chemoradiation followed by liver transplantation per Mayo Clinic protocol", "Repeat ERCP with cholangioscopy and targeted biopsies of the suspicious area", "Treat as benign dominant stricture with serial stenting and repeat CA 19-9 in 3 months"], "answer": "C", "answer_index": 2, "explanation": "In patients with PSC and suspected hilar cholangiocarcinoma, the Mayo Clinic protocol for neoadjuvant chemoradiation followed by liver transplantation requires strict diagnostic criteria including biopsy confirmation or strongly suggestive findings (CA 19-9 >100 U/mL, malignant-appearing stricture on imaging). PET SUV >5.0 with suspicious cytology meets criteria for protocol enrollment. Direct transplantation without protocol adherence risks transplanting unrecognized metastatic disease. Cholangioscopy and EUS-FNA have higher risks of peritoneal seeding in potentially resectable/transplantable cases.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Long-standing PSC with UC, new progressive jaundice, pruritus, weight loss; dominant hilar stricture with intrahepatic dilation on MRCP; CA 19-9 = 180 U/mL (>100); ERCP brushings “suspicious but not diagnostic”; PET-CT shows FDG-avid hilar lesion with SUVmax 6.2 (>5). These satisfy widely cited Mayo diagnostic criteria for presumed unresectable hilar cholangiocarcinoma in PSC eligible for the neoadjuvant chemoradiation + liver transplant protocol without mandatory positive biopsy.\\n\\nOption C correctly reflects protocol-based management. A is incorrect because standard practice is not to proceed directly to transplant outside an established protocol and staging; protocol-specific neoadjuvant therapy is required. B and D are disfavored because EUS-FNA or transperitoneal/extra-biliary biopsies can cause tumor seeding and exclude patients from transplant protocols. E is inappropriate given high-risk features and strong oncologic concern.\\n\\nMain medical accuracy: Description of Mayo criteria (CA 19-9 >100, malignant-appearing stricture, PET SUV >5 with suspicious cytology) is broadly consistent with published protocol concepts. \\n\\nMinimal fix: Clarify in the stem that the patient meets institutional criteria for the Mayo neoadjuvant transplantation protocol (e.g., lesion judged unresectable but confined to the hilum, no metastases on imaging).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Long-standing PSC with UC, new progressive jaundice, pruritus, weight loss; dominant hilar stricture with intrahepatic dilation on MRCP; CA 19-9 = 180 U/mL (>100); ERCP brushings “suspicious but not diagnostic”; PET-CT shows FDG-avid hilar lesion with SUVmax 6.2 (>5). These satisfy widely cited Mayo diagnostic criteria for presumed unresectable hilar cholangiocarcinoma in PSC eligible for the neoadjuvant chemoradiation + liver transplant protocol without mandatory positive biopsy.\n\nOption C correctly reflects protocol-based management. A is incorrect because standard practice is not to proceed directly to transplant outside an established protocol and staging; protocol-specific neoadjuvant therapy is required. B and D are disfavored because EUS-FNA or transperitoneal/extra-biliary biopsies can cause tumor seeding and exclude patients from transplant protocols. E is inappropriate given high-risk features and strong oncologic concern.\n\nMain medical accuracy: Description of Mayo criteria (CA 19-9 >100, malignant-appearing stricture, PET SUV >5 with suspicious cytology) is broadly consistent with published protocol concepts. \n\nMinimal fix: Clarify in the stem that the patient meets institutional criteria for the Mayo neoadjuvant transplantation protocol (e.g., lesion judged unresectable but confined to the hilum, no metastases on imaging).", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-002", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab for 5 years presents with fatigue and dark urine. Laboratory studies show hemoglobin 7.2 g/dL (baseline 10.5), LDH 850 U/L (baseline 300), haptoglobin <10 mg/dL, and negative direct antiglobulin test. She received her last eculizumab dose 12 days ago. Peripheral blood flow cytometry shows 95% PNH clone size (granulocytes). Complement C5 level is undetectable. Which of the following is the most likely explanation for her breakthrough hemolysis?", "options": ["Development of anti-eculizumab antibodies causing drug neutralization", "C5 gene polymorphism (c.2654G→A) resulting in eculizumab-resistant C5", "Concurrent mycoplasma pneumoniae infection with cold agglutinin production", "Functional deficiency of complement factor H due to acquired mutation", "Proximal complement pathway activation via C3 convertase amplification"], "answer": "B", "answer_index": 1, "explanation": "The c.2654G→A polymorphism in the C5 gene results in a single amino acid change (p.Arg885His) that prevents eculizumab binding while maintaining C5 function, leading to breakthrough hemolysis despite adequate drug levels. This autosomal dominant mutation affects approximately 3-4% of Japanese patients and requires switching to ravulizumab or other anti-C5 agents. Anti-drug antibodies are rare with eculizumab. Mycoplasma would cause cold agglutinin disease with positive DAT. Factor H deficiency causes atypical HUS, not PNH exacerbation.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: Known PNH on eculizumab, now with clear intravascular hemolysis (low haptoglobin, high LDH, negative DAT), 12 days after last dose, 95% granulocyte clone, undetectable C5 level. Question asks for the most likely explanation for breakthrough hemolysis.\\n\\nMain logical issue(s): Undetectable C5 in a patient on eculizumab indicates effective C5 blockade and does **not** support a C5 polymorphism that prevents drug binding; in that case, free C5 should be measurable and hemolysis continuous, not a dose‑timing “breakthrough.” The classic dose‑related (pharmacokinetic) breakthrough 10–14 days post‑dose is not offered as an option. Several distractors are clearly wrong (e.g., cold agglutinins would give a positive DAT), but no listed option is well supported by the lab data. Thus there is no clearly defensible single best answer, and the keyed choice (B) conflicts with the given complement level and time course.\\n\\nMain medical accuracy issue(s): The description of the C5 polymorphism is generally correct, but the vignette’s C5 level and intermittent “breakthrough” pattern are inconsistent with this mechanism.\\n\\nMinimal fix: Change the stem to state “free C5 level is within normal range despite eculizumab therapy” and indicate persistent (not dose‑timed) hemolysis; or change the key/choices to test PK-related breakthrough instead.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: Known PNH on eculizumab, now with clear intravascular hemolysis (low haptoglobin, high LDH, negative DAT), 12 days after last dose, 95% granulocyte clone, undetectable C5 level. Question asks for the most likely explanation for breakthrough hemolysis.\n\nMain logical issue(s): Undetectable C5 in a patient on eculizumab indicates effective C5 blockade and does **not** support a C5 polymorphism that prevents drug binding; in that case, free C5 should be measurable and hemolysis continuous, not a dose‑timing “breakthrough.” The classic dose‑related (pharmacokinetic) breakthrough 10–14 days post‑dose is not offered as an option. Several distractors are clearly wrong (e.g., cold agglutinins would give a positive DAT), but no listed option is well supported by the lab data. Thus there is no clearly defensible single best answer, and the keyed choice (B) conflicts with the given complement level and time course.\n\nMain medical accuracy issue(s): The description of the C5 polymorphism is generally correct, but the vignette’s C5 level and intermittent “breakthrough” pattern are inconsistent with this mechanism.\n\nMinimal fix: Change the stem to state “free C5 level is within normal range despite eculizumab therapy” and indicate persistent (not dose‑timed) hemolysis; or change the key/choices to test PK-related breakthrough instead.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-003", "question": "A 67-year-old man who underwent orthotopic liver transplantation 4 months ago for HCV cirrhosis presents with fever, cough, and hypoxemia. He is on tacrolimus and prednisone 5 mg daily. Chest CT shows multiple nodular opacities with surrounding ground-glass halos. Bronchoalveolar lavage PCR is positive for Torque teno virus (TTV) DNA at 10^8 copies/mL. Blood TTV viral load is 10^7 copies/mL. Which of the following is the most appropriate interpretation and management?", "options": ["TTV indicates severe immunosuppression; reduce tacrolimus dose and monitor for resolution", "TTV is a direct pulmonary pathogen; initiate intravenous ribavirin therapy", "TTV reactivation suggests CMV co-infection; start ganciclovir empirically", "TTV viral load has no clinical significance in this setting; pursue alternative diagnoses", "TTV indicates possible donor-derived infection; perform lung biopsy for histopathology"], "answer": "A", "answer_index": 0, "explanation": "Torque teno virus (TTV) viral load serves as a functional biomarker of overall immunosuppression in transplant recipients, with high levels indicating excessive immunosuppression and increased risk of opportunistic infections. The radiographic findings suggest invasive fungal infection (e.g., aspergillosis) in an over-immunosuppressed host. Reducing immunosuppression while evaluating for fungal pathogens is appropriate. TTV itself is not a pulmonary pathogen. There is no established antiviral therapy for TTV, and it does not specifically indicate CMV co-infection or donor-derived infection.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers; also partly U)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: 4 months post–liver transplant, on tacrolimus + low-dose prednisone, fever, cough, hypoxemia; CT with nodules and halo sign → highly suggestive of invasive mold (e.g., aspergillosis). BAL PCR shows high TTV load in BAL and blood. Question asks for “most appropriate interpretation and management.”\\nMedical reasoning: TTV is increasingly regarded as a biomarker of net immunosuppression; high loads correlate with over-immunosuppression and infection risk, matching the rationale for option A. However, choice A recommends a specific management step (reduce tacrolimus) without mention of any diagnostic evaluation or antifungal therapy, which is incomplete and somewhat risky given classic imaging for invasive aspergillosis.\\nChoice D correctly states that TTV has no direct clinical significance as a pathogen and implies that other diagnoses (e.g., invasive fungal infection) should be pursued; that is also true and clinically important. Because the stem does not explicitly ask about immunosuppression titration versus diagnostic workup priority, A and D are both reasonably defensible as “most appropriate,” creating ambiguity.\\nMinimal fix: Reword D to focus on TTV as non-pathogenic but a biomarker, or modify stem to ask specifically about TTV’s role in guiding immunosuppression.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers; also partly U)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: 4 months post–liver transplant, on tacrolimus + low-dose prednisone, fever, cough, hypoxemia; CT with nodules and halo sign → highly suggestive of invasive mold (e.g., aspergillosis). BAL PCR shows high TTV load in BAL and blood. Question asks for “most appropriate interpretation and management.”\nMedical reasoning: TTV is increasingly regarded as a biomarker of net immunosuppression; high loads correlate with over-immunosuppression and infection risk, matching the rationale for option A. However, choice A recommends a specific management step (reduce tacrolimus) without mention of any diagnostic evaluation or antifungal therapy, which is incomplete and somewhat risky given classic imaging for invasive aspergillosis.\nChoice D correctly states that TTV has no direct clinical significance as a pathogen and implies that other diagnoses (e.g., invasive fungal infection) should be pursued; that is also true and clinically important. Because the stem does not explicitly ask about immunosuppression titration versus diagnostic workup priority, A and D are both reasonably defensible as “most appropriate,” creating ambiguity.\nMinimal fix: Reword D to focus on TTV as non-pathogenic but a biomarker, or modify stem to ask specifically about TTV’s role in guiding immunosuppression.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-004", "question": "A 44-year-old woman with autoimmune hepatitis-primary biliary cholangitis overlap syndrome on ursodeoxycholic acid and budesonide develops recurrent episodes of severe, cramping abdominal pain with diarrhea occurring 30-60 minutes after meals. Symptoms improve with fasting. CT angiography shows no mesenteric ischemia. Gastric emptying study is normal. Upper endoscopy with duodenal biopsies shows villous blunting and intraepithelial lymphocytes. Serum tryptase during an episode is 45 ng/mL (normal <11.4). Which of the following is the most likely diagnosis?", "options": ["Mesenteric venous thrombosis with portal hypertensive enteropathy", "Systemic mastocytosis with gastrointestinal involvement", "Celiac disease with refractory sprue", "Abdominal angina from median arcuate ligament syndrome", "Bile acid malabsorption due to ileal dysfunction"], "answer": "B", "answer_index": 1, "explanation": "Systemic mastocytosis can present with postprandial abdominal pain, diarrhea, and flushing due to mast cell mediator release triggered by food. Elevated serum tryptase (>20 ng/mL) during symptoms is diagnostic. The duodenal findings represent mast cell infiltration rather than celiac disease. Mesenteric ischemia was ruled out by CT angiography. Median arcuate ligament syndrome causes epigastric pain but not diarrhea or elevated tryptase. Bile acid malabsorption does not explain the elevated tryptase or timing of symptoms.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recurrent severe crampy postprandial abdominal pain and diarrhea that improve with fasting; CT angiography excluding mesenteric ischemia; normal gastric emptying; duodenal biopsies with villous blunting and intraepithelial lymphocytes; and markedly elevated serum tryptase at 45 ng/mL (normal <11.4) during an episode. Elevated baseline/episodic tryptase >20 ng/mL is strongly associated with systemic mastocytosis, which commonly features GI symptoms (pain, diarrhea, sometimes malabsorption) and can cause histologic changes that mimic celiac disease. The negative ischemia work-up and lack of an ileal or portal-vein process further support a non-ischemic, non–bile acid diarrhea cause.\\nOption analysis: A is inconsistent with normal CT angiography and offers no basis for markedly high tryptase. Celiac disease/refractory sprue (C) fits the duodenal histology but does not explain the elevated tryptase, and there’s no gluten context or refractory course on therapy. D (median arcuate ligament) would explain postprandial pain but not diarrhea or tryptase elevation. E (bile acid malabsorption) would not elevate tryptase and usually follows ileal disease/resection, not present here.\\nMain medical issues: Minor overstatement in calling villous atrophy mast cell infiltration, but overall logic is sound.\\nMinimal fix: Clarify in rationale that mastocytosis can secondarily mimic celiac-type histology rather than redefining these changes outright.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recurrent severe crampy postprandial abdominal pain and diarrhea that improve with fasting; CT angiography excluding mesenteric ischemia; normal gastric emptying; duodenal biopsies with villous blunting and intraepithelial lymphocytes; and markedly elevated serum tryptase at 45 ng/mL (normal <11.4) during an episode. Elevated baseline/episodic tryptase >20 ng/mL is strongly associated with systemic mastocytosis, which commonly features GI symptoms (pain, diarrhea, sometimes malabsorption) and can cause histologic changes that mimic celiac disease. The negative ischemia work-up and lack of an ileal or portal-vein process further support a non-ischemic, non–bile acid diarrhea cause.\nOption analysis: A is inconsistent with normal CT angiography and offers no basis for markedly high tryptase. Celiac disease/refractory sprue (C) fits the duodenal histology but does not explain the elevated tryptase, and there’s no gluten context or refractory course on therapy. D (median arcuate ligament) would explain postprandial pain but not diarrhea or tryptase elevation. E (bile acid malabsorption) would not elevate tryptase and usually follows ileal disease/resection, not present here.\nMain medical issues: Minor overstatement in calling villous atrophy mast cell infiltration, but overall logic is sound.\nMinimal fix: Clarify in rationale that mastocytosis can secondarily mimic celiac-type histology rather than redefining these changes outright.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable; A is plausible but not clearly best.\\n\\nKey stem clues: 62-year-old man with JAK2+ essential thrombocythemia on hydroxyurea; acute left MCA infarct (platelets 450k); MRI shows multiple small enhancing lesions in both hemispheres; TTE shows no vegetations; blood cultures negative.\\n\\nIssue: The keyed mechanism (A, NBTE) requires cardiac vegetations, yet echo shows none and the lesions are described as parenchymal enhancing foci, not territorial infarcts from emboli. NBTE typically produces multiple territorial infarcts, and vegetations are often (though not always) seen on high-quality echo; the stem’s explicit “no vegetations” undercuts A as the single best answer. At the same time, none of the other options clearly explains the imaging pattern and clinical context; B–E are weak but not fully excluded by given data, so the item does not support a unique best choice.\\n\\nMain medical accuracy issue: Overstated link of essential thrombocythemia with NBTE; imaging description better fits multifocal CNS lesions than classic embolic infarcts.\\n\\nMinimal fix: Remove the statement “Transthoracic echocardiogram shows no vegetations” and explicitly describe small cortical infarcts consistent with emboli from NBTE, or change the keyed answer to another clearly supported mechanism and adjust stem accordingly.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable; A is plausible but not clearly best.\n\nKey stem clues: 62-year-old man with JAK2+ essential thrombocythemia on hydroxyurea; acute left MCA infarct (platelets 450k); MRI shows multiple small enhancing lesions in both hemispheres; TTE shows no vegetations; blood cultures negative.\n\nIssue: The keyed mechanism (A, NBTE) requires cardiac vegetations, yet echo shows none and the lesions are described as parenchymal enhancing foci, not territorial infarcts from emboli. NBTE typically produces multiple territorial infarcts, and vegetations are often (though not always) seen on high-quality echo; the stem’s explicit “no vegetations” undercuts A as the single best answer. At the same time, none of the other options clearly explains the imaging pattern and clinical context; B–E are weak but not fully excluded by given data, so the item does not support a unique best choice.\n\nMain medical accuracy issue: Overstated link of essential thrombocythemia with NBTE; imaging description better fits multifocal CNS lesions than classic embolic infarcts.\n\nMinimal fix: Remove the statement “Transthoracic echocardiogram shows no vegetations” and explicitly describe small cortical infarcts consistent with emboli from NBTE, or change the keyed answer to another clearly supported mechanism and adjust stem accordingly.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-006", "question": "A 31-year-old hematopoietic stem cell transplant recipient (day +45) for AML develops new-onset confusion and myoclonus. MRI brain shows symmetric T2 hyperintensities in the thalami and periaqueductal gray matter. CSF shows 5 WBCs/μL, protein 65 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). CSF PCR for HSV, VZV, EBV, CMV, and HHV-6 are negative. Metagenomic next-generation sequencing of CSF detects Astrovirus VA1/HMO-C RNA. Which of the following is the most appropriate management?", "options": ["Intravenous immunoglobulin 2 g/kg divided over 2-5 days", "Oral nitazoxanide 500 mg twice daily for 14 days", "Reduce immunosuppression and provide supportive care", "Intravenous ribavirin loading dose 33 mg/kg then 16 mg/kg every 6 hours", "Intrathecal administration of foscarnet 40 mg twice weekly"], "answer": "C", "answer_index": 2, "explanation": "Astrovirus VA1/HMO-C encephalitis in immunocompromised hosts has no proven antiviral therapy. Reduction of immunosuppression to allow immune reconstitution is the mainstay of management, along with supportive care. Intravenous immunoglobulin has been used but lacks proven efficacy. Nitazoxanide has in vitro activity but no clinical data in CNS infections. Ribavirin has poor CNS penetration and no proven benefit. Intrathecal foscarnet is used for HSV/VZV encephalitis but not for astrovirus.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Immunocompromised hematopoietic stem cell transplant recipient; subacute encephalitis with confusion and myoclonus; MRI showing symmetric thalamic and periaqueductal gray T2 hyperintensities (compatible with viral encephalitis pattern); CSF with mild pleocytosis and mildly elevated protein; negative PCR for common herpesviruses; metagenomic CSF sequencing positive for Astrovirus VA1/HMO‑C. These findings indicate astrovirus encephalitis in a severely immunocompromised host.\\n\\nAstrovirus VA1/HMO‑C CNS infection currently has no established, evidence‑based antiviral therapy. Case reports and reviews emphasize reduction of immunosuppression to permit immune reconstitution plus supportive care as the main management, making option C clearly best. IVIG, nitazoxanide, ribavirin, and intrathecal foscarnet have either only in vitro activity, anecdotal/unproven benefit, or are directed at other viruses; none is standard of care for astrovirus encephalitis, so they are appropriately inferior.\\n\\nThere are no internal contradictions or missing critical data; the metagenomic result explicitly identifies the pathogen, and the question asks for “most appropriate management,” which is to optimize host immunity and support.\\n\\nMinimal fix: Add a brief clause such as “There are no established antiviral regimens with proven efficacy against astrovirus VA1/HMO‑C” to reinforce the rationale but the item is already clear and defensible.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Immunocompromised hematopoietic stem cell transplant recipient; subacute encephalitis with confusion and myoclonus; MRI showing symmetric thalamic and periaqueductal gray T2 hyperintensities (compatible with viral encephalitis pattern); CSF with mild pleocytosis and mildly elevated protein; negative PCR for common herpesviruses; metagenomic CSF sequencing positive for Astrovirus VA1/HMO‑C. These findings indicate astrovirus encephalitis in a severely immunocompromised host.\n\nAstrovirus VA1/HMO‑C CNS infection currently has no established, evidence‑based antiviral therapy. Case reports and reviews emphasize reduction of immunosuppression to permit immune reconstitution plus supportive care as the main management, making option C clearly best. IVIG, nitazoxanide, ribavirin, and intrathecal foscarnet have either only in vitro activity, anecdotal/unproven benefit, or are directed at other viruses; none is standard of care for astrovirus encephalitis, so they are appropriately inferior.\n\nThere are no internal contradictions or missing critical data; the metagenomic result explicitly identifies the pathogen, and the question asks for “most appropriate management,” which is to optimize host immunity and support.\n\nMinimal fix: Add a brief clause such as “There are no established antiviral regimens with proven efficacy against astrovirus VA1/HMO‑C” to reinforce the rationale but the item is already clear and defensible.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]